Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
523,757

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $96.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Invest in NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investor confidence is currently high on NuVasive's (NUVA) prospects.

Edwards Lifesciences Sapien 3 System Recall Classified Class I

by Zacks Equity Research

Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on solid prospects of Bio-Rad (BIO).

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.

3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)

by Zacks Equity Research

Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here's Why You Should Invest in DaVita (DVA) Stock For Now

by Zacks Equity Research

DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.

Here's Why You Should Retain Nevro (NVRO) in Your Portfolio

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Here's Why You Should Retain Wright Medical Stock For Now

by Zacks Equity Research

Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space. However, forex remains a woe.

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Trina Mukherjee headshot

Outlook for Outpatient and Home Healthcare Industry Looks Bright

by Trina Mukherjee

Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.

Moving Average Crossover Alert: Amedisys

by Zacks Equity Research

Amedisys, Inc. (AMED) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Sumit Singh headshot

Tap These 5 Stocks With Amazing Interest Coverage Ratio

by Sumit Singh

Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.

Is Amedisys (AMED) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.

Zacks.com featured highlights include: Marine Products, Amedisys, Universal Forest Products, NVR and AllianceBernstein

by Zacks Equity Research

Zacks.com featured highlights include: Marine Products, Amedisys, Universal Forest Products, NVR and AllianceBernstein

Amedisys (AMED) Q2 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Robust year-over-year growth in Medicare and non-Medicare revenues aids Amedisys' (AMED) Home Health and Hospice divisions.

Company News for Aug 1, 2019

by Zacks Equity Research

Companies In The News Are: HABT, ZNGA, AMED, CHEF

Sanghamitra Saha headshot

Play DuPont Technique to Land on 5 Top-Ranked Stocks

by Sanghamitra Saha

Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.

Amedisys (AMED) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amedisys (AMED) delivered earnings and revenue surprises of 24.74% and 0.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: M.D.C., Amedisys, KBR, Holly Energy and SkyWest

by Zacks Equity Research

The Zacks Analyst Blog Highlights: M.D.C., Amedisys, KBR, Holly Energy and SkyWest

Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More

by Zacks Equity Research

Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.

Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?

by Zacks Equity Research

Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.

Nalak Das headshot

5 Must-Buy Mid-Cap Stocks Ahead of Q2 Earnings This Week

by Nalak Das

Mid-cap stocks have rallied in 2019. These stocks can become very useful in a volatile trading scenario.

Is a Beat in Store for Molina Healthcare (MOH) Q2 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) second-quarter earnings are likely to be cushioned by its strategic divestitures as well as cost-reduction plans, partly offset by lower revenues.

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

by Zacks Equity Research

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.